These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 14747566)

  • 1. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
    Newman JT; Riggs JM; Surman SR; McAuliffe JM; Mulaikal TA; Collins PL; Murphy BR; Skiadopoulos MH
    J Virol; 2004 Feb; 78(4):2017-28. PubMed ID: 14747566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.
    Bartlett EJ; Castaño A; Surman SR; Collins PL; Skiadopoulos MH; Murphy BR
    Virol J; 2007 Jul; 4():67. PubMed ID: 17605811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.
    Bartlett EJ; Amaro-Carambot E; Surman SR; Newman JT; Collins PL; Murphy BR; Skiadopoulos MH
    Vaccine; 2005 Sep; 23(38):4631-46. PubMed ID: 15951066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates.
    Bartlett EJ; Amaro-Carambot E; Surman SR; Collins PL; Murphy BR; Skiadopoulos MH
    Vaccine; 2006 Mar; 24(14):2674-84. PubMed ID: 16364511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.
    Skiadopoulos MH; Tatem JM; Surman SR; Mitcho Y; Wu SL; Elkins WR; Murphy BR
    Vaccine; 2002 Mar; 20(13-14):1846-52. PubMed ID: 11906774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.
    Bartlett EJ; Cruz AM; Boonyaratanakornkit J; Esker J; Castaño A; Skiadopoulos MH; Collins PL; Murphy BR; Schmidt AC
    Vaccine; 2010 Jan; 28(3):767-79. PubMed ID: 19857454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.
    Skiadopoulos MH; Surman SR; St Claire M; Elkins WR; Collins PL; Murphy BR
    Virology; 1999 Jul; 260(1):125-35. PubMed ID: 10405364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
    Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR
    Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human parainfluenza virus 3 vaccine candidates attenuated by codon-pair deoptimization are immunogenic and protective in hamsters.
    Afroz S; Saul S; Dai J; Surman S; Liu X; Park HS; Le Nouën C; Lingemann M; Dahal B; Coleman JR; Mueller S; Collins PL; Buchholz UJ; Munir S
    Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2316376121. PubMed ID: 38861603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.
    Nolan SM; Skiadopoulos MH; Bradley K; Kim OS; Bier S; Amaro-Carambot E; Surman SR; Davis S; St Claire M; Elkins R; Collins PL; Murphy BR; Schaap-Nutt A
    Vaccine; 2007 Aug; 25(34):6409-22. PubMed ID: 17658669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.
    McAuliffe JM; Surman SR; Newman JT; Riggs JM; Collins PL; Murphy BR; Skiadopoulos MH
    J Virol; 2004 Feb; 78(4):2029-36. PubMed ID: 14747567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1.
    Van Cleve W; Amaro-Carambot E; Surman SR; Bekisz J; Collins PL; Zoon KC; Murphy BR; Skiadopoulos MH; Bartlett EJ
    Virology; 2006 Aug; 352(1):61-73. PubMed ID: 16750233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
    Tao T; Skiadopoulos MH; Durbin AP; Davoodi F; Collins PL; Murphy BR
    Vaccine; 1999 Mar; 17(9-10):1100-8. PubMed ID: 10195620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses.
    Nolan SM; Surman SR; Amaro-Carambot E; Collins PL; Murphy BR; Skiadopoulos MH
    Vaccine; 2005 Sep; 23(39):4765-74. PubMed ID: 15964103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees.
    Skiadopoulos MH; Surman SR; Riggs JM; Elkins WR; St Claire M; Nishio M; Garcin D; Kolakofsky D; Collins PL; Murphy BR
    Virology; 2002 May; 297(1):153-60. PubMed ID: 12083845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics.
    Newman JT; Surman SR; Riggs JM; Hansen CT; Collins PL; Murphy BR; Skiadopoulos MH
    Virus Genes; 2002; 24(1):77-92. PubMed ID: 11928991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.